Novo Nordisk looks to shore up European market share


Novo Nordisk, the world's biggest maker of diabetes drugs, will focus on growing volumes rather than price in its key European market where it has lost ground to competitors in recent years, a senior executive said on Friday. Novo Nordisk's share of the European insulin market, its biggest outside North America, has gradually dropped in the last 6-7 years to around 45 percent.



from Biotech News